Aagami, Inc. | Strategic Consulting, Technology Licensing, Business Research & Market Intelligence, Business Development support

Latest News

New Assignment from Past Client for Out-Licensing their Topical Lidocaine Patch (Patented) awaiting FDA approval

Aagami has received a new assignment from their publicly listed Japanese client, to help them out-license Topical Lidocaine Patch (Patented) for the U...

New Client Win: Biopharma company Uncoupling Metastasis and Proliferation with translational platform, ML and known molecules to disrupt cancer treatment. Lead asset in Phase 2 stage

We are glad to announce that Aagami has been appointed by a new client who are “Metastasis Specialists” uncoupling Metastasis and Proliferat...

New Client Win: Ann Arbor company focused on improving cancer survival with a smart targeted drug delivery platform

We are pleased to announce that Aagami has been appointed by a US based Biopharma to help them raise investments. About the Client: Ann Arbo...

“ We are pleased by Aagami Team’s good work, in a professional and gracious manner. We would be delighted to recommend your services to others ”

CEO of a Oregon, US based Biotech

“ The virtues of working with Aagami include the team’s attentiveness to us and to the potential partners, persistence in follow-up and most of all, integrity”

Founder and CEO of a California based Biopharma

“ While we think we understand business, terminology and customs change from Country to Country. Without having an intimate knowledge of these differences, a gap if you will, it is difficult if not impossible to transact equitable arrangements. Aagami is the bridge that crosses this gap. Importantly it does so openly and honestly”

Founder and CEO of a publicly Listed Australian Technology Development Company

“ We have worked with many Consultants in US and Canada, however, in our experience, none of them are worthy of even standing in Aagami’s Shadow. We are blessed to have Aagami on our side. ”

CEO of a Specialty Chemicals company based in North America

The service provided was excellent. Everything was handled in a thorough & professional manner. A large number of opportunities were identified, facilitated and progressed to a conclusion.

VP of a UK based Pharma

Aagami Team are Very Professional and Prompt in communication

Founder of a US Labware Consumables Company

Aagami laid out a pretty clear process and stuck to it, which is not often the case when engaging advisors for BD assignments. Also Aagami were very well connected. We had the opportunity to sign two deals via Aagami, which we had not anticipated.

Stephen Yoder, CEO, Pieris Pharmaceuticals

Honest and transparent communication. Dedicated approach, hard working

Martin Welschof, CEO, Opsona Therapeutics

"We were very satisfied with the outcome, and the final report, along with much additional data from subsequent trials conducted by our current licensees, now forms a part of our extensive Drug Master File at the FDA."

Edward T. Maggio, PhD, CEO of Aegis Therapeutics (Currently Consultant to Neurelis, who purchased Aegis at the end of November 2018)

"Professional and disciplined approach to execution of the project."

Sr. VP of a NY based Pharma (Now a part of Endo)

Business Development support in regions
where you are unable to reach out due to bandwidth

Business Research
and Market Intelligence Services

Deep Experience of overcoming business
and socio-cultural differences of various countries

Why

Value Proposition

120+

210+

250+

500+

What We Do

Services

In/Out Licensing

Partnership / Co-Development

Funding / Investment

Mergers & Acquisitions

Market Entry,
Market Development Strategy

Finding the Right Partners

Success Stories

Help us understand your needs

Latest News

New Assignment from Past Client for Out-Licensing their Topical Lidocaine Patch (Patented) awaiting FDA approval

New Client Win: Biopharma company Uncoupling Metastasis and Proliferation with translational platform, ML and known molecules to disrupt cancer treatment. Lead asset in Phase 2 stage

New Client Win: Ann Arbor company focused on improving cancer survival with a smart targeted drug delivery platform

Testimonials

“ We are pleased by Aagami Team’s good work, in a professional and gracious manner. We would be delighted to recommend your services to others ”

“ The virtues of working with Aagami include the team’s attentiveness to us and to the potential partners, persistence in follow-up and most of all, integrity”

“ We have worked with many Consultants in US and Canada, however, in our experience, none of them are worthy of even standing in Aagami’s Shadow. We are blessed to have Aagami on our side. ”

The service provided was excellent. Everything was handled in a thorough & professional manner. A large number of opportunities were identified, facilitated and progressed to a conclusion.

Aagami Team are Very Professional and Prompt in communication

Aagami laid out a pretty clear process and stuck to it, which is not often the case when engaging advisors for BD assignments. Also Aagami were very well connected. We had the opportunity to sign two deals via Aagami, which we had not anticipated.

Honest and transparent communication. Dedicated approach, hard working

"We were very satisfied with the outcome, and the final report, along with much additional data from subsequent trials conducted by our current licensees, now forms a part of our extensive Drug Master File at the FDA."

"Professional and disciplined approach to execution of the project."

Social Media

Contact Us

Locate Us

Subscribe Us

Business Development support in regionswhere you are unable to reach out due to bandwidth

Business Research and Market Intelligence Services

Deep Experience of overcoming businessand socio-cultural differences of various countries

Why

Value Proposition

120+

210+

250+

500+

What We Do

Services

In/Out Licensing

Partnership / Co-Development

Funding / Investment

Mergers & Acquisitions

Market Entry,Market Development Strategy

Finding the Right Partners

Success Stories

Help us understand your needs

Latest News

New Assignment from Past Client for Out-Licensing their Topical Lidocaine Patch (Patented) awaiting FDA approval

New Client Win: Biopharma company Uncoupling Metastasis and Proliferation with translational platform, ML and known molecules to disrupt cancer treatment. Lead asset in Phase 2 stage

New Client Win: Ann Arbor company focused on improving cancer survival with a smart targeted drug delivery platform

Testimonials

“ We are pleased by Aagami Team’s good work, in a professional and gracious manner. We would be delighted to recommend your services to others ”

“ The virtues of working with Aagami include the team’s attentiveness to us and to the potential partners, persistence in follow-up and most of all, integrity”

“ We have worked with many Consultants in US and Canada, however, in our experience, none of them are worthy of even standing in Aagami’s Shadow. We are blessed to have Aagami on our side. ”

The service provided was excellent. Everything was handled in a thorough & professional manner. A large number of opportunities were identified, facilitated and progressed to a conclusion.

Aagami Team are Very Professional and Prompt in communication

Aagami laid out a pretty clear process and stuck to it, which is not often the case when engaging advisors for BD assignments. Also Aagami were very well connected. We had the opportunity to sign two deals via Aagami, which we had not anticipated.

Honest and transparent communication. Dedicated approach, hard working

"We were very satisfied with the outcome, and the final report, along with much additional data from subsequent trials conducted by our current licensees, now forms a part of our extensive Drug Master File at the FDA."

"Professional and disciplined approach to execution of the project."

Business Development support in regions
where you are unable to reach out due to bandwidth

Business Research
and Market Intelligence Services

Deep Experience of overcoming business
and socio-cultural differences of various countries

Market Entry,
Market Development Strategy